Literature DB >> 26972647

Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation.

Brent S Rose1, Kyung-Wook Jee2, Andrzej Niemierko2, Janet E Murphy3, Lawrence S Blaszkowsky3, Jill N Allen3, Leslie K Lee4, Yingbing Wang4, Lorraine C Drapek2, Theodore S Hong2, Jennifer Y Wo2.   

Abstract

PURPOSE: Irradiation of pelvic bone marrow (BM) has been correlated with hematologic toxicity (HT) in patients undergoing chemoradiation for anal cancer. We hypothesized that irradiation of hematologically active bone marrow (ABM) subregions defined by fluorodeoxyglucose (FDG) positron emission tomography (PET) is a principal cause of radiation-associated HT. METHODS AND MATERIALS: The cohort included 45 patients with nonmetastatic anal cancer who underwent FDG-PET imaging prior to definitive chemoradiation with mitomycin-C and 5-fluorouracil. Total bone marrow (TBM) was defined as the external contour of the pelvic bones from the top of lumbar 5 (L5) to the bottom of the ischial tuberosity. Standardized uptake values (SUV) for all voxels within the TBM were quantified and normalized by comparison to normal liver SUV. Subvolumes of the TBM that exhibited the highest and lowest 50% of the SUVs were designated ABM50 and IBM50, respectively. The primary endpoint was the absolute neutrophil count (ANC) nadir during or within 2 weeks of completion of treatment. Multivariate linear modeling was used to analyze the correlation between the equivalent uniform doses (EUD) with an a value of 0.5, 1 (equivalent to mean dose), 3, 7, and 12 to the BM structures and the ANC.
RESULTS: Mean ± SD ANC nadir was 0.77 × 10(9)/L (±0.66 × 10(9)/L). Grades 3 and 4 ANC toxicity occurred in 26.7% and 44.4% of patients, respectively. The EUD a parameter of 0.5 was optimal for all BM models indicating high radiation sensitivity. EUD of TBM and ABM50 and IBM50 were all significantly associated with ANC nadir. However, model performance for ABM50 was not superior to that of the TBM and IBM50 models.
CONCLUSIONS: Irradiation of pelvic BM was associated with HT. However, FDG-PET-defined ABM models failed to improve model performance compared to the TBM model.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26972647     DOI: 10.1016/j.ijrobp.2015.12.006

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients.

Authors:  Pierfrancesco Franco; Francesca Arcadipane; Riccardo Ragona; Adriana Lesca; Elena Gallio; Massimiliano Mistrangelo; Paola Cassoni; Vincenzo Arena; Sara Bustreo; Riccardo Faletti; Nadia Rondi; Mario Morino; Umberto Ricardi
Journal:  Med Oncol       Date:  2016-06-08       Impact factor: 3.064

2.  Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer.

Authors:  Azadeh Abravan; Hanne Astrid Eide; Ayca Muftuler Løndalen; Åslaug Helland; Eirik Malinen
Journal:  Mol Imaging Biol       Date:  2019-04       Impact factor: 3.488

3.  Dosimetric Comparison of Intensity-Modulated Proton Therapy and Volumetric-Modulated Arc Therapy in Anal Cancer Patients and the Ability to Spare Bone Marrow.

Authors:  Teresa Meier; Anthony Mascia; Eric Wolf; Jordan Kharofa
Journal:  Int J Part Ther       Date:  2017-12-28

4.  Feasibility of bone marrow sparing volumetric modulated arc therapy to spare active bone marrow in cervical and vaginal cancer patients: a retrospective dosimetric analysis.

Authors:  Michaela Beavan; Kylie Dundas; Felicity Hudson; Yolanda Surjan; Annie Lau; Shrikant Deshpande; Karen Lim; Viet Do
Journal:  J Med Radiat Sci       Date:  2021-07-19

5.  Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation.

Authors:  Pierfrancesco Franco; Christian Fiandra; Francesca Arcadipane; Elisabetta Trino; Francesca Romana Giglioli; Riccardo Ragona; Umberto Ricardi
Journal:  BMC Cancer       Date:  2017-11-02       Impact factor: 4.430

6.  Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo-Radiation: Results of the First Phase of a Prospective Phase II Trial.

Authors:  Francesca Arcadipane; Patrick Silvetti; Francesco Olivero; Alessio Gastino; Viola De Luca; Massimiliano Mistrangelo; Paola Cassoni; Patrizia Racca; Elena Gallio; Adriana Lesca; Christian Fiandra; Umberto Ricardi; Pierfrancesco Franco
Journal:  Cancers (Basel)       Date:  2020-11-09       Impact factor: 6.639

7.  Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer.

Authors:  Łukasz Kuncman; Konrad Stawiski; Michał Masłowski; Jakub Kucharz; Jacek Fijuth
Journal:  Strahlenther Onkol       Date:  2020-07-03       Impact factor: 3.621

8.  Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.

Authors:  Martin P Nilsson; Anders Johnsson; Jonas Scherman
Journal:  Radiat Oncol       Date:  2021-08-16       Impact factor: 3.481

9.  Concurrent Chemoradiation in Anal Cancer Patients Delivered with Bone Marrow-Sparing IMRT: Final Results of a Prospective Phase II Trial.

Authors:  Francesca Arcadipane; Patrick Silvetti; Francesco Olivero; Alessio Gastino; Roberta Carlevato; Ilaria Chiovatero; Lavinia Spinelli; Massimiliano Mistrangelo; Paola Cassoni; Giuliana Ritorto; Elena Gallio; Adriana Lesca; Riccardo Faletti; Francesca Romana Giglioli; Christian Fiandra; Umberto Ricardi; Pierfrancesco Franco
Journal:  J Pers Med       Date:  2021-05-18

10.  Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer.

Authors:  Maxwell Robinson; Rebecca Muirhead; Clare Jacobs; Rosie Cooke; Kwun-Ye Chu; Frank Van den Heuvel; Stasya Ng; Pradeep Virdee; Victoria Strauss; Maria Hawkins
Journal:  Radiother Oncol       Date:  2019-09-07       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.